HIGHLIGHTS
- who: Basil Mohammed Alomair and colleagues from the Aljouf University, Sakaka, Saudi Arabia have published the research work: Montelukast and Acute Coronary Syndrome: The Endowed Drug, in the Journal: Pharmaceuticals 2022, 15, 1147. of /2022/
- what: The present review had many limitations, including a paucity of clinical studies that evaluate the clinical effectiveness of MK in patients with ACS.
SUMMARY
Acute coronary syndrome (ACS) is a set of signs and symptoms caused by a reduction of coronary blood flow with subsequent myocardial ischemia. According to the electrocardiographic (ECG) changes and duration . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.